Curative Biotechnology's "Non-Dilutive" Promise Is the Part That Hasn't Happened

The shareholder letter Curative Biotechnology (OTC: CUBT) published in November 2025 read like a micro-cap finding its footing. A development-stage eye-disease biotech developing metformin eye drops licensed from the National Institutes of Health, it announced a "new path to value creation": shut down its planned stock offering, shrink its share count 150-for-1, and pay for its first human trial not with shareholder money but with cash from a partner that would sublicense the drug and hand over non-dilutive funding via upfront and clinical milestone payments.

For a stock that funds itself by selling shares, that last clause was the entire offer. It is also the clause that hasn't come true yet.

A real asset, an aging market

Start with what's actually there. Curative is an OTC micro-cap focused on dry age-related macular degeneration, a large and still under-served condition, using a topical metformin ophthalmic formulation it holds under an exclusive worldwide license from the National Eye Institute, part of the NIH. Metformin is a cheap, decades-old diabetes drug, but the retinal-protective idea behind repurposing it is backed by real academic work, and the technology has drawn patent allowances in Canada (January 2026) and the United States (July 2026), strengthening the platform.

The letter's plan had four distinct pillars: partner out manufacturing and product development for non-dilutive cash, terminate the public offering and withdraw the S-1, execute a 150-to-1 reverse split, and uplist to the OTCQB Venture Market. Two of those are structural housekeeping that changes nothing about value. One, the promised sublicense, is where the money is supposed to come from — and it remains unproven. And the uplisting depends on the partnership materializing.

The split happened; the money didn't

The reverse split did go through, effective March 23, 2026, collapsing roughly 1.02 billion shares into about 6.8 million. But a reverse split changes nothing about ownership percentages and nothing about the value of the enterprise. For a serial capital raiser it is usually a dress rehearsal — it makes the share count look tidier and moves a company closer to exchange-qualified status, but it does not fund a single patient.

Set that against what the "new path" was actually for. The company's own estimate from its SEC filings was that a combined Phase I/II human trial would run about $6.1 million, and the economics of the whole story depend on funding that out of something other than more share issuance. Yet in its quarterly report filed in May 2025 it carried a working capital deficit of roughly $6.9 million and an accumulated deficit near $42.9 million. In plain terms, it ended the period with more current liabilities than current assets. A company in that position has no built-up way to pay for a first-in-human study at NIH, a parallel veterinary trial, and the manufacturing to support both.

So the pivotal question is whether the non-dilutive sublicense actually lands. And here is where the letter's promise and its follow-through diverge: what materialized in April 2026 was not a value-accretive licensing deal that pays Curative an upfront fee. It was a manufacturing services agreement with Sterling Pharmaceutical Services, a contract manufacturer. That is a vendor Curative pays to produce clinical supply — the same direction as spending money, not the opposite. The cash-producing, dilution-avoiding partnership at the center of the shareholder letter has not closed as of this writing.

The clever part worth keeping

None of this is a reason to dismiss the science. The thing that makes the story genuinely interesting is the company running human and veterinary development in parallel. The same eye-drop program, aimed at retinal degeneration in dogs, qualifies for the FDA's Center for Veterinary Medicine conditional approval pathway, which can permit commercialization for up to five years while confirmatory data is gathered — a faster, cheaper route to actual revenue than the decade-long human drug cycle, and one that feeds translational data back toward the human program. It is a sensible way to de-risk, and it orients the business toward a real market rather than pure speculation.

That is the constructive case, and it stands. But it does not change the arithmetic of who is paying for the trials. In my opinion, the single fact that would validate the entire "new path" is a signed sublicense with real cash up front. Until that lands, investors should be exact about what the reverse split and the uplisting mechanics have actually achieved: they have reorganized the capital structure, not paid for the clinical program.

For a beginner investor, the lesson is straightforward: in an OTC development-stage company running largely on press releases, do not let share-count gymnastics read as value creation, and do not take "non-dilutive" at face value when the balance sheet still has no funded path from here to a first readout. Watch whether a partner actually pays. That is the one number that separates a new path from new marketing.